杭州绿哲医药

Hangzhou Luzhe Medicine Technology Co., Ltd. is a Chinese biotechnology company focused on the discovery and development of innovative small molecule drugs and protein degradation therapies. The company leverages advanced R&D platforms to target complex diseases, with a primary focus on oncology and solid tumors. Luzhe Medicine is notably supported by Hangzhou Bio-100 Pharmaceutical Technology, a leading CRO that holds a minority stake in the company and provides integrated R&D services. Its lead research efforts include the development of PI3K-targeting PROTAC molecules for the treatment of advanced breast and lung cancers. The company is headquartered in Hangzhou and operates as part of the region's growing life sciences ecosystem.